Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Tetsuichiro Isono"'
Autor:
Yuki Kunitsu, Daiki Hira, Aya Morikochi, Tomohiro Ueda, Tetsuichiro Isono, Shin-ya Morita, Tomohiro Terada
Publikováno v:
PLoS ONE, Vol 17, Iss 2 (2022)
Acute kidney injury (AKI) associated with “Triple Whammy” drug therapy consisting of renin-angiotensin system inhibitors, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) has been reported. There have been no reports investigating “
Externí odkaz:
https://doaj.org/article/fd692070abac41d78e5a2d2a5b0c07e6
Autor:
Tetsuichiro Isono, Daiki Hira, Aya Morikochi, Tadateru Fukami, Satoshi Ueshima, Kazuhiko Nozaki, Tomohiro Terada, Shin‐ya Morita
Publikováno v:
Pharmacology Research & Perspectives, Vol 9, Iss 6, Pp n/a-n/a (2021)
Abstract High‐dose methotrexate (HD‐MTX)‐based chemotherapy is the first‐line treatment for primary central nervous system lymphoma (PCNSL), but is associated with severe adverse effects, including myelosuppression and renal impairment. MTX i
Externí odkaz:
https://doaj.org/article/824d53c5e02641dda3a283c8be708d12
Autor:
Yuichi Sawayama, Yukinori Tomita, Soji Kohyama, Yosuke Higo, Kenji Kodama, Kohei Asada, Noriaki Yagi, Megumi Fukuyama, Atsushi Hayashi, Wataru Shioyama, Hiroshi Sakai, Tomoya Ozawa, Tetsuichiro Isono, Daiki Hira, Takashi Yamamoto, Shin-ya Morita, Yoshihisa Nakagawa
Publikováno v:
Circulation Journal. 87:755-763
Autor:
Tetsuichiro Isono, Daiki Hira, Yoshito Ikeda, Masahiro Kawahara, Satoshi Noda, Atsushi Nishida, Osamu Inatomi, Noriki Fujimoto, Akira Andoh, Tomohiro Terada, Shin-ya Morita
Publikováno v:
Biological and Pharmaceutical Bulletin. 46:412-418
Autor:
Hiroshi Sakai, Megumi Fukuyama, Tomohiro Terada, Kohei Asada, Daiki Hira, Noriaki Yagi, Yuichi Sawayama, Akashi Miyamoto, Yukinori Tomita, Minoru Horie, Yoshihisa Nakagawa, Tomoya Ozawa, Takashi Yamamoto, Tetsuichiro Isono
Publikováno v:
Circulation Journal. 84:1575-1581
BACKGROUND The association between cytochrome P450 (CYP) 2C19 genotypes and adverse events in patients treated with clopidogrel or prasugrel after percutaneous coronary intervention (PCI) in the Japanese population is unclear.Methods and Results:This
Autor:
Tadateru Fukami, Daiki Hira, Aya Morikochi, Tomohiro Terada, Satoshi Ueshima, Tetsuichiro Isono, Shin-ya Morita, Kazuhiko Nozaki
Publikováno v:
Pharmacology Research & Perspectives, Vol 9, Iss 6, Pp n/a-n/a (2021)
Pharmacology Research & Perspectives
Pharmacology Research & Perspectives
High‐dose methotrexate (HD‐MTX)‐based chemotherapy is the first‐line treatment for primary central nervous system lymphoma (PCNSL), but is associated with severe adverse effects, including myelosuppression and renal impairment. MTX is primari
Autor:
Yuki Kunitsu, Daiki Hira, Aya Morikochi, Tomohiro Ueda, Tetsuichiro Isono, Shin-ya Morita, Tomohiro Terada
Publikováno v:
PLoS ONE, Vol 17, Iss 2, p e0263682 (2022)
PLoS ONE, Vol 17, Iss 2 (2022)
PLoS ONE, Vol 17, Iss 2 (2022)
Acute kidney injury (AKI) associated with “Triple Whammy” drug therapy consisting of renin-angiotensin system inhibitors, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) has been reported. There have been no reports investigating “
Autor:
Hideki Itoh, Tomohiro Terada, Tetsuichiro Isono, Satoshi Ueshima, Daiki Hira, Rika Fukui, Yuki Kunitsu, Yohei Tabuchi, Yoshihiro Ikuno, Toshihiro Tanaka
Publikováno v:
Journal of Clinical Biochemistry and Nutrition
In clinical practice, edoxaban is sometimes prescribed for off-label use based on the hypothesis that it is as safe and effective as warfarin. However, there is limited safety information on off-label use due to lack of clinical trial. We aimed to an
Publikováno v:
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. 139(11)
Recently, there have been reports that the combination of renin angiotensin inhibitors, diuretics, and non-steroidal anti-inflammatory drugs increases the risk of acute kidney injury (AKI). This combination has been dubbed the "Triple Whammy". Howeve
Autor:
Takashi Uzu, Kyoko Masuda, Yuki Kunitsu, Tetsuichiro Isono, Hisazumi Araki, Shin-ichi Araki, Tomohiro Terada, Daiki Hira
Publikováno v:
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 43:601-609